Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS

References

• Joint United Nations Program on HIV/AIDSWorld AIDS Day Report – 2011GenevaUNAIDS2011 Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdfAccessed August 26, 2013
   Google Scholar
• RossDABehavioural interventions to reduce HIV risk: what works?AIDS201024Suppl 4S4S1421042051
   PubMed Web of Science ®Google Scholar
• De ClercqEThe history of antiretrovirals: key discoveries over the past 25 yearsRev Med Virol200919528729919714702
   PubMed Web of Science ®Google Scholar
• EsteJACihlarTCurrent status and challenges of antiretroviral research and therapyAntiviral Res2010851253320018390
   PubMed Web of Science ®Google Scholar
• DybulMFauciASBartlettJGKaplanJEPauAKGuidelines for using antiretroviral agents among HIV-infected adults and adolescentsAnn Intern Med20021375 Pt 238143312617573
   PubMed Web of Science ®Google Scholar
• GrantRMLamaJRAndersonPLPreexposure chemoprophylaxis for HIV prevention in men who have sex with menN Engl J Med2010363272587259921091279
   PubMed Web of Science ®Google Scholar
• HofmanPNelsonAMThe pathology induced by highly active anti-retroviral therapy against human immunodeficiency virus: an updateCurr Med Chem200613263121313217168701
   PubMed Web of Science ®Google Scholar
• AgwuALindseyJCFergusonKAnalyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapyAIDS Patient Care STDS200822754555218479228
   PubMed Web of Science ®Google Scholar
• KeeferMCGrahamBSBelsheRBStudies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1 seronegative humans. The AIDS Vaccine Clinical Trials NetworkAIDS Res Hum Retroviruses19941012171317237888231
   PubMed Web of Science ®Google Scholar
• McElrathMJCoreyLGreenbergPDHuman immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimenProc Natl Acad Sci U S A1996939397239778633000
   PubMed Web of Science ®Google Scholar
• GilbertPBPetersonMLFollmannDCorrelation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trialJ Infect Dis2005191566667715688279
   PubMed Web of Science ®Google Scholar
• RussellNDGrahamBSKeeferMCPhase 2 study of an HIV-1 canarypox vaccine (vCP 1452) alone and in combination with rgp 120: negative results fail to trigger a phase 3 correlates trialJ Acquir Immune Defic Syndr200744220321217106277
   PubMed Web of Science ®Google Scholar
• BuchbinderSPMehrotraDVDuerrAEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialLancet200837296531881189319012954
   PubMed Web of Science ®Google Scholar
• de SouzaMSRatto-KimSChuenaromWThe Thai phase III trial (RV144) vaccine regimen induces T-cell responses that preferentially target epitopes within the V2 region of HIV-1 envelopeJ Immunol2012188105166517622529301
   PubMed Web of Science ®Google Scholar
• WalkerLMPhogatSKChan-HuiPYBroad and potent neutral-izing antibodies from an African donor reveal a new HIV-1 vaccine targetScience2009326595028528919729618
   PubMed Web of Science ®Google Scholar
• KwongPDMascolaJRNabelGJRational design of vaccines to elicit broadly neutralizing antibodies to HIV-1Cold Spring Harb Perspect Med201111a00727822229123
   PubMed Web of Science ®Google Scholar
• WalkerLMHuberMDooresKJBroad neutralization coverage of HIV by multiple highly potent antibodiesNature2011477736546647021849977
   PubMed Web of Science ®Google Scholar
• DoncelGMauckCVaginal microbicides: a novel approach to preventing sexual transmission of HIVCurr HIV/AIDS Rep200411253216091220
   PubMedGoogle Scholar
• ZewdieDHolschneiderSExpanding on preventing options: the role of the international community in providing an enabling environment of microbicidesAIDS200115Suppl 1S5S611293386
   PubMed Web of Science ®Google Scholar
• KlebanoffSJCoombsRWVirucidal effect of Lactobacillus aci-dophilus on human immunodeficiency virus type 1: possible role in heterosexual transmissionJ Exp Med199117412892921647436
   PubMed Web of Science ®Google Scholar
• KlatzmannDChampagneEChamaretST-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAVNature198431259967677686083454
   PubMed Web of Science ®Google Scholar
• AlkhatibGCombadiereCBorderCCCC CKR5: a RANTES, MIP-1 alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1Science19962725270195519588658171
   PubMed Web of Science ®Google Scholar
• FengYBroderCCKennedyPEBergerEAHIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptorScience199627252638728778629022
   PubMed Web of Science ®Google Scholar
• BergerEAMurphyPMFarberJMChemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and diseaseAnnu Rev Immunol19991765770010358771
   PubMed Web of Science ®Google Scholar
• FreedEOHIV-1 gag protein: diverse functions in the virus life cycleVirology199825111159813197
   PubMed Web of Science ®Google Scholar
• HaaseATPerils at mucosal front lines for HIV and SIV and their hostsNat Rev Immunol200551078379216200081
   PubMed Web of Science ®Google Scholar
• GuthrieBLKiarieJNMorrisonSSexually transmitted infections among HIV-1-discordant couplesPLoS One2009412e827620011596
   PubMed Web of Science ®Google Scholar
• LagaMManokaAKivuvuMNon-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort studyAIDS199371951028442924
   PubMed Web of Science ®Google Scholar
• BourinbaiarASFruhstorferECThe efficacy of nonoxynol-9 from an in vitro point of viewAIDS19961055585598724057
   PubMed Web of Science ®Google Scholar
• MillerCJAlexanderNJGettieAHendrickxAGMarxPAThe effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaquesFertil Steril1992575112611281315297
   PubMed Web of Science ®Google Scholar
• Van DammeLRamjeeGAlaryMEffectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trialLancet2002360933897197712383665
   PubMed Web of Science ®Google Scholar
• StaffordMKWardHFlanaganASafety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effectsJ Acquir Immune Defic Syndr Hum Retrovirol19981743273319525433
   PubMedGoogle Scholar
• WyrickPBKnightSTGerbigDGJrThe microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitroAntimicrob Agents Chemother1997416133513449174195
   PubMed Web of Science ®Google Scholar
• KrebsFCMillerSRCataloneBJSodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytesAntimicrob Agents Chemother20004471954196010858360
   PubMed Web of Science ®Google Scholar
• PetersonLNandaKOpokuBKSAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double blind, randomized, placebo-controlled trial in GhanaPLoS One2007212e131218091987
   PubMed Web of Science ®Google Scholar
• FeldblumPJAdeigaABakareRSAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in NigeriaPLoS One200831e147418213382
   PubMed Web of Science ®Google Scholar
• PiretJDesormeauxABergeronMGSodium lauryl sulfate, a microbi-cide effective against enveloped and nonenveloped virusesCurr Drug Targets200231173011899262
   PubMed Web of Science ®Google Scholar
• Mbopi-KeouFXTrottierSOmarRFA randomized, double-blind, placebo-controlled phase II extended safety study of two invisible condom formulations in Cameroonian womenContraception2010811798520004278
   PubMed Web of Science ®Google Scholar
• HuskensDVermeireKProfyATScholsDThe candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1Antiviral Res2009841384719664662
   PubMed Web of Science ®Google Scholar
• KellerMJZerhouni-LayachiBCheshenkoNPRO2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trialJ Infect Dis20061931273516323128
   PubMed Web of Science ®Google Scholar
• AbdoolKarimSSResults of effectiveness trials of PRO2000 gel: lessons for future microbicide trialsFuture Microbiol20105452752920353292
   PubMed Web of Science ®Google Scholar
• SchaefferDJKrylovVSAnti-HIV activity of extracts and compounds from algae and cyanobacteriaEcotoxicol Environ Saf200045320822710702339
   PubMed Web of Science ®Google Scholar
• PerottiMEPirovanoAPhillipsDMCarrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide developmentBiol Reprod200369393393912773428
   PubMed Web of Science ®Google Scholar
• Skoler-KarpoffSRamjeeGAhmedKEfficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trialLancet200837296541977198719059048
   PubMed Web of Science ®Google Scholar
• Scordi-BelloIAMosoianAHeCCandidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of actionAntimicrob Agents Chemother20054993607361516127029
   PubMed Web of Science ®Google Scholar
• FuchsEJLeeLATorbensonMSHyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmissionJ Infect Dis2007195570371017262713
   PubMed Web of Science ®Google Scholar
• HalpernVOgunsolaFObungeOEffectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in NigeriaPLoS One2008311e378419023429
   PubMed Web of Science ®Google Scholar
• NeurathARStrickNLiYYWater dispersible microbicidal cellulose acetate phthalate filmBMC Infect Dis200332714617380
   PubMed Web of Science ®Google Scholar
• LuHZhaoQWallaceGCellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolatesAIDS Res Hum Retroviruses200622541141816706617
   PubMed Web of Science ®Google Scholar
• FichorovaRNZhouFRatnamVAnti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammationAntimicrob Agents Chemother200549132333515616312
   PubMed Web of Science ®Google Scholar
• NeurathARStrickNLiYYLinKJiangSDesign of a “microbi-cide” for prevention of sexually transmitted diseases using “inactive” pharmaceutical excipientsBiologicals1999271112110441398
   PubMed Web of Science ®Google Scholar
• LaceyCJWoodhallSQiZUnacceptable side effects associated with a hyperosmolar vaginal microbicide in a phase 1 trialInt J STD AIDS2010211071471721139151
   PubMed Web of Science ®Google Scholar
• KawamuraTGuldenFOSugayaMR5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphismsProc Natl Acad Sci U S A2003100148401840612815099
   PubMed Web of Science ®Google Scholar
• VeazeyRSLingBGreenLCTopically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challengeJ Infect Dis2009199101525152719331577
   PubMed Web of Science ®Google Scholar
• BabaMNishimuraOKanzakiNA small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activityProc Natl Acad Sci U S A199996105698570310318947
   PubMed Web of Science ®Google Scholar
• VeazeyRSKlassePJSchaderSMProtection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusionNature200543870649910216258536
   PubMed Web of Science ®Google Scholar
• VeazeyRSKetasTJDufourJProtection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptorJ Infect Dis2010202573974420629537
   PubMed Web of Science ®Google Scholar
• HatseSPrincenKGerlachLOMutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100Mol Pharmacol200160116417311408611
   PubMed Web of Science ®Google Scholar
• AllawayGPDavis-BrunoKLBeaudryGAExpression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolatesAIDS Res Hum Retroviruses19951155335397576908
   PubMed Web of Science ®Google Scholar
• BurtonDRPyatiJKoduriREfficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibodyScience19942665187102410277973652
   PubMed Web of Science ®Google Scholar
• BalzariniJVan LaethemKHatseSCarbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the Achilles heel of HIVJ Biol Chem200528049410054101416183648
   PubMed Web of Science ®Google Scholar
• BoydMRGustafsonKRMcMohanJBDiscovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide developmentAntimicrob Agents Chemother1997417152115309210678
   PubMed Web of Science ®Google Scholar
• SwansonMDWinterHCGoldsteinIJMarkovitzDMA lectin isolated from bananas is a potent inhibitor of HIV replicationJ Biol Chem2010285128646865520080975
   PubMed Web of Science ®Google Scholar
• BuffaVStiehDMamhoodNHuQFletcherPShattockRJCyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant modelsJ Gen Virol200990Pt 123424319088294
   PubMed Web of Science ®Google Scholar
• TsaiCCEmauPJiangYCyanovirin-N gel as a topical micro-bicide prevents rectal transmission of SHIV89.6P in macaquesAIDS Res Hum Retroviruses200319753554112921090
   PubMed Web of Science ®Google Scholar
• TsaiCCEmauPJiangYCyanovirin-N inhibits AIDS virus infections in vaginal transmission modelsAIDS Res Hum Retroviruses2004201111815000694
   PubMed Web of Science ®Google Scholar
• LiuXLagenaurLALeePPXuQEngineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 moleculesAppl Environ Microbiol200874154626463518539799
   PubMed Web of Science ®Google Scholar
• VangelistaLSecchiMLiuXEngineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockersAntimicrob Agents Chemother20105472994300120479208
   PubMed Web of Science ®Google Scholar
• BalzariniJTargeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIVLancet Infect Dis200551172673116253890
   PubMed Web of Science ®Google Scholar
• WildCTShugarsDCGreenwellTKMcDanalCBMatthewsTJPeptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infectionProc Natl Acad Sci U S A19949121977097747937889
   PubMed Web of Science ®Google Scholar
• KilbyJMEronJJNovel therapies based on mechanisms of HIV-1 cell entryN Engl J Med2003348222228223812773651
   PubMed Web of Science ®Google Scholar
• KetasTJSchaderSMZuritaJEntry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypesVirology2007364243144017428517
   PubMed Web of Science ®Google Scholar
• TyssenDHendersonSAJohnsonAStructure activity relationship of dendrimer microbicides with dual action antiviral activityPLoS One201058e1230920808791
   PubMed Web of Science ®Google Scholar
• O’LoughlinJMillwoodIYMcDonaldHMPriceCFKaldorJMPaullJRSafety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I studySex Transm Dis201037210010419823111
   PubMed Web of Science ®Google Scholar
• ZwickMBWangMPoignardPNeutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodiesJ Virol20017524121981220811711611
   PubMed Web of Science ®Google Scholar
• ParikhUMDobardCSharmaSComplete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabineJ Virol20098320103581036519656878
   PubMed Web of Science ®Google Scholar
• DobardCSharmaSMartinADouble protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissuesJ Virol201286271872522072766
   PubMed Web of Science ®Google Scholar
• MayerKHMaslankowskiLAGaiFSafety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected womenAIDS200620454355116470118
   PubMed Web of Science ®Google Scholar
• Abdool KarimQAbdool KarimSSFrohlichJAEffectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenScience201032959961168117420643915
   PubMed Web of Science ®Google Scholar
• TanDPotential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in femalesInt J Womens Health2012434135022927765
   PubMedGoogle Scholar
• Van der StratenAVan DammeLHabererJEBangsbergDRUnraveling the divergent results of pre-exposure prophylaxis trials for HIV preventionAIDS2012267F13F1922333749
   PubMed Web of Science ®Google Scholar
• Van HerrewegeYMichielsJVan RoeyJIn vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicidesAntimicrob Agents Chemother200448133733914693562
   PubMed Web of Science ®Google Scholar
• FletcherPHarmanSAzijnHInhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitorAntimicrob Agents Chemother200953248749519029331
   PubMed Web of Science ®Google Scholar
• Di FabioSVan RoeyJGianniniGInhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulationAIDS200317111597160412853741
   PubMed Web of Science ®Google Scholar
• YangHParniakMAIsaacsCEHillierSLRohanLCCharacterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781AAPS J200810460661319089644
   PubMed Web of Science ®Google Scholar
• VernazzaPWangCPozniakAEfficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trialJ Acquir Immune Defic Syndr201362217117923328090
   PubMed Web of Science ®Google Scholar
• WainbergMAMesplèdeTQuashiePKThe development of novel HIV integrase inhibitors and the problem of drug resistanceCurr Opin Virol20122565666222989757
   PubMed Web of Science ®Google Scholar
• MarchandCThe elvitegravir Quad pill: the first once-daily dual-target anti-HIV tabletExpert Opin Investig Drugs2012217901904
   PubMed Web of Science ®Google Scholar
• ZolopaASaxPEDeJesusEA randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsJ Acquir Immune Defic Syndr20136319610023392460
   PubMed Web of Science ®Google Scholar
• MartinHLRichardsonBANyangePMVaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisitionJ Infect Dis199918061863186810558942
   PubMed Web of Science ®Google Scholar
• Abdool KarimSSRichardsonBARamjeeGSafety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in womenAIDS201125795796621330907
   PubMed Web of Science ®Google Scholar
• AmaralEFaúndesAZaneveldLWallerDGargSStudy of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gelContraception199960636136610715372
   PubMed Web of Science ®Google Scholar
• HemmerlingAPottsMWalshJYoung-HoltBWhaleyKStefanskiDALime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginallyJ Womens Health (Larchmt)20071671041105117903081
   PubMed Web of Science ®Google Scholar
• RamjeeGMorarNSBraunsteinSFriedlandBJonesHvan de WijgertJAcceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South AfricaAIDS Res Ther200742017900337
   PubMedGoogle Scholar
• ColyAGarbachPMMicrobicide acceptability research: recent findings and evolution across phases of product developmentCurr Opin HIV AIDS20083558158619373025
   PubMed Web of Science ®Google Scholar
• NelAMMitchnickLBRishaPMuungoLTNorichPMAcceptability of vaginal film, soft-gel capsule and tablet as potential microbicide delivery methods among African womenJ Womens Health (Larchmt)20112081207121421774672
   PubMed Web of Science ®Google Scholar
• JoglekarNSJoshiSNDeshpandeSSParkheANKattiURMehendaleSMAcceptability and adherence: findings from a phase II study of a candidate vaginal microbicide, ‘Praneempolyherbal tablet’, in Pune, IndiaTrans R Soc Trop Med Hyg2010104641241520096909
   PubMed Web of Science ®Google Scholar
• RobertsonAMSyvertsenJLMartinezGAcceptability of vaginal microbicides among female sex workers and their intimate male partners in two Mexico-US border cities: a mixed methods analysisGlob Public Health20138561963323398385
   PubMed Web of Science ®Google Scholar
• KiserPFJohnsonTJClarkJTState of the art in intravaginal ring technology for topical prophylaxis of HIV infectionAIDS Rev2012141627722297505
   PubMed Web of Science ®Google Scholar
• MalcolmKFetherstonSMMcCoyCFBoydPMajorIVaginal rings for delivery of HIV microbicidesInt J Womens Health2012459560523204872
   PubMedGoogle Scholar
• NovakAde la LogeCAbetzLvan der MeulenEAThe combined contraceptive vaginal ring, NuvaRing: an international study of user acceptabilityContraception200367318719412618252
   PubMed Web of Science ®Google Scholar
• ClarkJTJohnsonTJClarkMRQuantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovirJ Control Release2012163224024822981701
   PubMed Web of Science ®Google Scholar
• JohnsonTJClarkMRAlbrightTHA 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxisAntmicrob Agents Chemother2012561262726283
   Web of Science ®Google Scholar
• MesquitaPMRastogiRSegarraTJIntravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infectionJ Antimicrob Chemother20126771730173822467632
   PubMed Web of Science ®Google Scholar
• SmithDJWakasiakaSHoangTDBwayoJJDel RioCPriddyFHAn evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: Behaviors and attitudes that might influence uptake within a high-risk populationJ Womens Health (Larchmt)20081761025103418681822
   PubMed Web of Science ®Google Scholar
• FetherstonSMBoydPMcCoyCFA silicon elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of actionEur J Pharm Sci201248340641523266465
   PubMed Web of Science ®Google Scholar
• ArensMTravisSZinc salts inactivate clinical isolates of herpes simplex virus in vitroJ Clin Microbiol20003851758176210790094
   PubMed Web of Science ®Google Scholar
• BuckCBThompsonCDRobertsJNMüllerMLowyDRSchillerJTCarrageenan is a potent inhibitor of papillomavirus infectionPLoS Pathog200627e6916839203
   PubMed Web of Science ®Google Scholar
• SingerRDerbyNRodriguezAThe nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaquesJ Virol201185115504551221411526
   PubMed Web of Science ®Google Scholar
• Fernández-RomeroJAAbrahamCJRodriguezAZinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challengeAntimicrob Agents Chemother201256135836822064530
   PubMed Web of Science ®Google Scholar
• FriendDRDoncelGFCombining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologiesAntiviral Res201088Suppl 1S47S5421109068
   PubMed Web of Science ®Google Scholar
• BallCKrogstadEChaowanachanTWoodrowKADrug-eluting fibers for HIV-1 inhibition and contraceptionPLoS One2012711e4979223209601
   PubMed Web of Science ®Google Scholar
• FletcherPSElliottJGrivelJCEx vivo culture of human colorectal tissue for the evaluation of candidate microbicidesAIDS20062091237124516816551
   PubMed Web of Science ®Google Scholar
• CumminsJEJrGuarnerJFlowersLPreclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant cultureAntimicrob Agents Chemother20075151770177917353237
   PubMed Web of Science ®Google Scholar
• HzelmBEBertaANNickersonCAArntzenCJHerbst-KralovetzMMDevelopment and characterization of a three-dimensional organotypic human vaginal epithelial cell modelBiol Reprod201082361762720007410
   PubMed Web of Science ®Google Scholar
• CumminsJEJrDoncelGFBiomarkers of cervicovaginal inflammation for the assessment of microbicide safetySex Transm Dis200936Suppl 3S84S9119218890
   PubMed Web of Science ®Google Scholar
• DentonPWEstesJDSunZAntiretroviral preexposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT micePLoS Med200851e1618198941
   PubMed Web of Science ®Google Scholar
• LiLZYangYYuanSHEstablishing a Th17 based mouse model for preclinical assessment of the toxicity of candidate microbicidesChin Med J (Engl)2010123233381338822166518
   PubMed Web of Science ®Google Scholar
• VincentKLBoumeNBellBAHigh resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicidesSex Transm Dis200936531231819295469
   PubMed Web of Science ®Google Scholar
• TienDSchnaareRLKangFIn vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trialsAIDS Res Hum Retroviruses2005211084585316225411
   PubMed Web of Science ®Google Scholar
• SchwartzJLBallaghSAKwokCFourteen-day safety and acceptability study of the universal placebo gelContraception200775213614117241844
   PubMed Web of Science ®Google Scholar
• MoenchTRO’HanlonDConeEEvaluation of microbicide gel adherence monitoring methodsSex Transm Dis201239533534022504592
   PubMed Web of Science ®Google Scholar
• News-Medical.net [website on the Internet]FDA approves Gilead’s Stribild to treat HIV-1 infection2012 Available from: http://www.news-medical.net/news/20120828/FDA-approves-Gileade28099s-Stribild-to-treat-HIV-1-infection.aspxAccessed August 26, 2013
   Google Scholar
• Femail.com.au [website on the Internet]VivaGel new clinical trial commences Available from: http://www.femail.com.au/vivagel-new-clinical-trial-commences.htmAccessed August 26, 2013
   Google Scholar